- HOME
- Portfolio
Portfolio
Deep pipeline of novel compounds, each with the potential to be first or best-in-class treatments for unmet patient needs
AskAt’s strategy centers on utilizing this global, integrated collaboration network to continually add value to each of its candidate programs.
Out-licensed Programs
| Program | Disease | Discovery | Non-Clinical | Clinical | Registration | Launch | Region of Develop. (Sales) |
Development Company |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | Phase 2 | Phase 3 | |||||||||
| Program | Indication | Phase | Development Region |
Partner | |||||||
| AAT-007 EP4 antagonist |
Cancer
|
P1 Ongoing | US | Ikena | |||||||
| P1 Ongoing | China | NewBay | |||||||||
|
Pain
|
P1 Completed | China | ３DM | ||||||||
|
Pain/Inflammation (Animal) |
Launched | (JP, US, EU,& Others) | Elanco | ||||||||
| AAT-008 EP4 antagonist |
Cancer
|
Non-clin. Completed | US | Ikena | |||||||
|
Non-clin. Completed (P1-IND approved) |
China | NewBay | |||||||||
|
Pain/Inflammation (Animal) |
Non-clin. Ongoing | JP, US, EU,& Others | Elanco | ||||||||
| AAT-076 COX-2 inhibitor |
Pain
|
P1 Ongoing | China | ３DM | |||||||
| AAT-730 CB2 agonist |
Pain
|
Non-clin. Ongoing | UK | OCT | |||||||
In-house Development and Business Development Programs
| Program | Disease | Discovery | Non-Clinical | Clinical | Area Of License | |||
|---|---|---|---|---|---|---|---|---|
| Phase 1 | Phase 2 | Phase 3 | ||||||
| Program | Indication | Phase | Area Of License | |||||
|
AAT-009
5-HT4 partial agonist |
Dementia
|
P1 Completed (US) |
All | |||||
|
Cognitive Impairment (Animal) |
Discovery Completed |
All | ||||||
| AAT-076 COX-2 inhibitor |
Pain
|
P2a Completed (US, Acute Pain) |
All except for China |
|||||
|
Pain/Inflammation (Animal) |
Discovery Completed |
All | ||||||
| AAT-730 CB2 agonist |
Pain & Neuronal Diseases |
Discovery Completed |
Japan | |||||
|
Pain/Inflammation (Animal) |
Discovery Completed |
All | ||||||
AskAt's license
| Program | Indication/ Route/ Others |
Partners | Territory | R&D Stage |
|---|---|---|---|---|
| AAT-007 | Cancer and all other human diseases (oral) | Ikena Oncology | Worldwide except China and Taiwan | Clinical |
| NewBay | China | Clinical | ||
| Pain | Haihe | China | Clinical | |
| Topical | license opportunity available |
Worldwide | Pre-clinical | |
| Animal Health | Aratana/Elanco | Worldwide | Marketed (Dog) | |
| AAT-008 | Cancer and all other human diseases (oral) | Ikena Oncology | Worldwide except China and Taiwan | Pre-clinical |
| NewBay | China | Pre-clinical | ||
| Pain | license opportunity available |
China | Pre-clinical | |
| Animal Health | Aratana | Worldwide | Pre-clinical | |
| Autoimmune Disease |
license opportunity available |
China | Pre-clinical | |
| Topical | license opportunity available |
Pre-clinical | ||
| AAT-009 | Dementia | license opportunity available |
Worldwide | Clinical |
| AAT-076 | Cancer | license opportunity available |
Worldwide | Clinical |
| Pain | Haihe | China | Clinical | |
| license opportunity available |
Worldwide except China |
Clinical | ||
| All potential indications except Cancer and Pain |
license opportunity available |
Worldwide | Pre-clinical/ clinical |
|
| AAT-730 | All potential indications |
OCT | Worldwide except Japan |
Pre-clinical |
| license opportunity available |
Japan | Discovery |
